Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure-Reference-Cited by-同舟云学术

Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure

Published:2019-03-05 Issue:7 Volume:14 Page:1083-1090
ISSN:1828-0447
Container-title:Internal and Emergency Medicine
language:en
Short-container-title:Intern Emerg Med

Author:

Bertero Edoardo,Miceli Roberta,Lorenzoni Alessandra,Balbi Manrico,Ghigliotti Giorgio,Chiarella Francesco,Brunelli Claudio,Viazzi Francesca,Pontremoli Roberto,Canepa Marco,Ameri Pietro^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Emergency Medicine,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11739-019-02060-0.pdf

Reference29 articles.

1. CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med 316(23):1429–1435. https://doi.org/10.1056/nejm198706043162301

2. Investigators SOLVD, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293–302. https://doi.org/10.1056/NEJM199108013250501

3. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362(9386):772–776. https://doi.org/10.1016/S0140-6736(03)14284-5

4. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 362(9386):767–771. https://doi.org/10.1016/S0140-6736(03)14283-3

5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. https://doi.org/10.1093/eurheartj/ehw128

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of chronic obstructive pulmonary disease on long-term hospitalization and mortality in patients with heart failure with reduced ejection fraction;BMC Pulmonary Medicine;2023-02-17

2. Long‐term risk of heart failure and other adverse cardiovascular outcomes in primary Sjögren's syndrome;Journal of Internal Medicine;2022-12-11

3. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?;European Heart Journal - Cardiovascular Pharmacotherapy;2021-05-26

4. Cancer in chronic heart failure patients in the GISSI‐HF trial;European Journal of Clinical Investigation;2020-05-31

5. Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study;Internal and Emergency Medicine;2019-05-30